Q-omics provides the consensus-scored MIR27A profile across patient tissues and cancer cell-line models. MIR27A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR27A is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, MIR27A RNA expression shows 12,645 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, BLCA, and THYM as cancer lineages where MIR27A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR27A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR27A survival associations across molecular data types. MIR27A RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR27A RNA expression–survival associations across cancer types. High MIR27A expression shows unfavorable associations in ACC, MESO, LGG, THCA and GBM, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR27A RNA expression.
This table summarizes MIR27A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR27A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR27A shows lower tumor expression in BLCA, KICH, LUAD, BRCA, KIRP and KIRC. The BLCA box plot shows higher MIR27A RNA expression in normal versus tumor tissue (log2 FC = −2.600, t-test p < 0.001).
This table shows molecular features associated with MIR27A in patient tissues and cancer cell lines. In patient samples, MIR27A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
